Clariant TEA extension request
This article was originally published in The Tan Sheet
Executive Summary
Piroctone olamine manufacturer Clariant seeks 90-day extension to "assemble a comprehensive submission" to FDA on the safety and efficacy of the anti-dandruff ingredient. Firm requests original deadline of May 18 be pushed back to Aug. 16, Washington, D.C. law firm Keller & Heckman says in a letter to FDA filed April 16 on behalf of Clariant. The agency issued a call for safety and efficacy data on piroctone olamine as a single active dandruff control ingredient in February to determine its eligibility for monograph status. Review follows submission of a time and extent application by Clariant...
You may also be interested in...
Piroctone olamine TEA extension
FDA grants manufacturer Clariant's request for a 90-day extension of public comment period for anti-dandruff ingredient safety and efficacy review to August 16. The agency "considers an extension of time for submission of data, information and general comments concerning the safety and effectiveness of piroctone olamine to be in the public interest," according to a May 19 Federal Register 1notice. Clariant had requested more time to assemble a "more comprehensive" submission (2"The Tan Sheet" May 10, 2004, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.